A 2-year-old girl presents with coarse facial features, corneal clouding, hepatosplenomegaly, and stiff joints. Her urine shows elevated heparan sulfate and dermatan sulfate. Which is the most specific investigation to confirm the diagnosis of mucopolysaccharidosis type I (Hurler syndrome)?

## Diagnostic Confirmation of Mucopolysaccharidosis Type I (Hurler Syndrome) ### Clinical Presentation Recognition The constellation of **coarse features, corneal clouding, hepatosplenomegaly, joint stiffness, and elevated urinary heparan sulfate + dermatan sulfate** is diagnostic of **MPS I (Hurler syndrome)**. The patient has already been biochemically screened via urine GAG analysis. ### Investigation Hierarchy for MPS Diagnosis | Investigation | Timing | Diagnostic Value | Specificity | |---|---|---|---| | **Leukocyte α-L-iduronidase assay** | First-line enzyme confirmation | Directly measures the deficient enzyme | **Highly specific for MPS I** | | Urine GAG quantification/electrophoresis | Screening | Confirms elevated GAG excretion; pattern suggests MPS type | Non-specific; multiple MPS types show heparan + dermatan sulfate | | Skeletal X-ray | Staging/monitoring | Shows dysostosis multiplex; confirms skeletal involvement | Non-specific; present in many MPS types | | Fibroblast culture for enzyme assay | Confirmatory alternative | Measures enzyme in fibroblasts; slower | More time-consuming; used if leukocyte assay unavailable | ### Why Leukocyte α-L-Iduronidase Is Most Specific **Key Point:** α-L-iduronidase deficiency is the **pathognomonic enzyme defect** in MPS I. Measuring this enzyme directly in leukocytes is the gold standard for confirming the diagnosis. **High-Yield:** MPS I has **three clinical phenotypes** (all with the same enzyme deficiency): - **Hurler (Type I-H)**: Severe; onset < 2 years; death by age 10 - **Hurler-Scheie (Type I-HS)**: Intermediate; slower progression - **Scheie (Type I-S)**: Mild; normal intelligence; survival to adulthood **Clinical Pearl:** Despite phenotypic variation, **all three forms have the same enzyme defect** — α-L-iduronidase deficiency. Enzyme assay cannot distinguish phenotype; clinical severity and age of onset do. ### Why Urine GAG Analysis Is Screening, Not Diagnostic Urine GAG electrophoresis shows **elevated heparan sulfate and dermatan sulfate**, which is consistent with MPS I, but this pattern is **not unique**: - MPS I, II, and VII all show heparan + dermatan sulfate elevation - MPS III (Sanfilippo) shows predominantly heparan sulfate - MPS IV (Morquio) shows predominantly keratan sulfate **Warning:** Urine GAG pattern alone **cannot distinguish between MPS types**. Enzyme assay is required for specific diagnosis. ### Diagnostic Algorithm ```mermaid flowchart TD A[Clinical suspicion: Coarse features + corneal clouding + HSM + stiff joints]:::outcome --> B[Urine GAG screening]:::action B --> C{Elevated heparan + dermatan sulfate?}:::decision C -->|Yes| D[Differential: MPS I, II, or VII]:::outcome D --> E[Leukocyte enzyme panel]:::action E --> F{α-L-iduronidase deficient?}:::decision F -->|Yes| G[MPS I confirmed]:::outcome F -->|No| H[Check other enzymes: iduronate sulfatase, β-glucuronidase]:::action ``` ### Tissue Source for Enzyme Assay **High-Yield:** Enzyme assays for MPS can be performed on: 1. **Leukocytes** (white blood cells) — fastest, most accessible 2. **Fibroblasts** (skin biopsy culture) — alternative if leukocyte assay unavailable 3. **Plasma** — less sensitive; not preferred 4. **Dried blood spot** — emerging newborn screening method Leukocyte assay is preferred because it is **rapid, non-invasive, and cost-effective**. ### Why Skeletal X-ray Is Not Diagnostic Skeletal X-rays show **dysostosis multiplex** (abnormal bone development, vertebral changes, short stature), which is a feature of many MPS types. It is useful for **staging severity and monitoring progression**, but it does not identify the specific enzyme deficiency. [cite:Robbins 10e Ch 5; Harrison 21e Ch 356]